Vishal Bhatnagar, MD (@vishalbmd) 's Twitter Profile
Vishal Bhatnagar, MD

@vishalbmd

Associate Director for Patient Outcomes, Oncology Center of Excellence. FDA. Interested in MM and patient focused drug development. Opinions/tweets are my own

ID: 935170815577948166

calendar_today27-11-2017 15:37:51

40 Tweet

258 Followers

123 Following

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

We're getting ready to welcome you online tomorrow, July 17, for the FDA-ASCO Clinical Outcome Assessments in Cancer Clinical Trials Fifth Annual Workshop! #OCEOutcomes20 ow.ly/p6aH50AAceq

We're getting ready to welcome you online tomorrow, July 17, for the FDA-<a href="/ASCO/">ASCO</a> Clinical Outcome Assessments in Cancer Clinical Trials Fifth Annual Workshop! #OCEOutcomes20
ow.ly/p6aH50AAceq
Ramez Kouzy, MD (@rkouzymd) 's Twitter Profile Photo

Really excited to hear about project patient voice which will allow healthcare providers to access PRO data collected from cancer trials. This will allow providers to be armed with information that can guide treatment expectations #OCEoutcomes20 #PROs

Mel Calvert (@drmelcalvert) 's Twitter Profile Photo

Why timing really matters in #pro assessment. Bellinda King-Kallimanis describes how we may miss important side effects if we assess #PROs day 1 of treatment cycle -are frequent brief assessments the way forward? #OCEOutcomes20 Paul Kluetz Vishal Bhatnagar, MD FDA Oncology CPROR

Ishwaria Subbiah, MD MS FASCO (@ishwariamd) 's Twitter Profile Photo

Folks you can't ask the right question at the wrong time! Timing of #PRO measurements must adapt as #cancer treatments (esp. their mechanisms, targets, etc) evolve!! FDA Oncology's Sundeep Agrawal tackles the timing challenge at ASCO FDA Oncology #OCEOutcomes20!

Folks you can't ask the right question at the wrong time! Timing of #PRO measurements must adapt as #cancer treatments (esp. their mechanisms, targets, etc) evolve!! <a href="/FDAOncology/">FDA Oncology</a>'s Sundeep Agrawal tackles the timing challenge at <a href="/ASCO/">ASCO</a> <a href="/FDAOncology/">FDA Oncology</a> #OCEOutcomes20!
Paul Kluetz (@pkluetz) 's Twitter Profile Photo

Like this panel, trial design for #PRO needs clinician, psychometrician, statistician and patient input! Expected toxicity and timing, right tool, strong analysis methods and objectives that are meaningful to patients. #OCEOutcomes20

Paul Kluetz (@pkluetz) 's Twitter Profile Photo

Informative visualization of the timing of FDA review when multiple expedited programs are put in place. A lot goes into hastening the availability of novel treatments for patients with cancer...

Scott Gottlieb, MD 🇺🇸 (@scottgottliebmd) 's Twitter Profile Photo

FDA’s professional staff have acted with a sense of high urgency during Covid, driven by a shared sense of public health mission; issuing over 60 guidances on accelerating Covid innovation, 750 drugs in mid or late stage trials, a huge review team focused on Covid therapeutics.

FDA’s professional staff have acted with a sense of high urgency during Covid, driven by a shared sense of public health mission; issuing over 60 guidances on accelerating Covid innovation, 750 drugs in mid or late stage trials, a huge review team focused on Covid therapeutics.
NEJM (@nejm) 's Twitter Profile Photo

Why has the United States handled this pandemic so badly? The Editors note that although we came into this crisis with enormous advantages, our current political leaders have demonstrated that they are dangerously incompetent.

NFL on ESPN (@espnnfl) 's Twitter Profile Photo

Mo Gaba, who battled cancer and was blind, became part of the fabric in the Baltimore sports community and made a lasting impact on the Ravens. Mo died on July 28, 2020, but his legacy continues to carry on.

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Did you know that #FDAOncology supports applied regulatory science research to address practical problems in oncology therapy development? Check out FDA’s Broad Agency Announcement. ow.ly/Xw6r50D3Au1 More info at the #OCEScientificCollaborative: fda.gov/about-fda/onco…

Did you know that #FDAOncology supports applied regulatory science research to address practical problems in oncology therapy development? Check out FDA’s Broad Agency Announcement.  ow.ly/Xw6r50D3Au1
More info at the #OCEScientificCollaborative:  fda.gov/about-fda/onco…
Media Affairs (@fdamedia) 's Twitter Profile Photo

Today, the FDA issued draft guidance to address which patient-reported outcomes to measure in cancer clinical trials. go.usa.gov/x6KwC

FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Mark your calendar and register for the FDA 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop focused on patient-reported outcomes in open-label trials. June 29, 2022, 10am-3pm ET #OCEOutcomes22 with Paul Kluetz Vishal Bhatnagar, MD Erica Horodniceanu fda.gov/news-events/fd…

Mark your calendar and register for the FDA 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop focused on patient-reported outcomes in open-label trials. June 29, 2022, 10am-3pm ET #OCEOutcomes22 with <a href="/pkluetz/">Paul Kluetz</a> <a href="/vishalbmd/">Vishal Bhatnagar, MD</a> <a href="/EGHorod/">Erica Horodniceanu</a>
fda.gov/news-events/fd…
FDA Oncology (@fdaoncology) 's Twitter Profile Photo

FDA Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop. June 29, 2022. Agenda and session panelist biographies now posted. Click to view full event details. #OCEOutcomes22 with Paul Kluetz Vishal Bhatnagar, MD Erica Horodniceanu bit.ly/39WunoN

FDA Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop. June 29, 2022. Agenda and session panelist biographies now posted. Click to view full event details. #OCEOutcomes22 with <a href="/pkluetz/">Paul Kluetz</a> <a href="/vishalbmd/">Vishal Bhatnagar, MD</a> <a href="/EGHorod/">Erica Horodniceanu</a>
bit.ly/39WunoN
FDA Oncology (@fdaoncology) 's Twitter Profile Photo

Today's the day for FDA's 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop on patient-reported outcomes in open-label trials! 6/29/22 - 10am-3pm ET #OCEOutcomes22 with Paul Kluetz Vishal Bhatnagar, MD #patientreportedoutcomes bit.ly/39WunoN

Today's the day for FDA's 7th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop on patient-reported outcomes in open-label trials! 6/29/22 - 10am-3pm ET #OCEOutcomes22 with <a href="/pkluetz/">Paul Kluetz</a> <a href="/vishalbmd/">Vishal Bhatnagar, MD</a> #patientreportedoutcomes
bit.ly/39WunoN